Moderna’s stock declined as much as 25% on Thursday following an unintended disclosure of preliminary information regarding its personalized cancer vaccine, developed in partnership with Merck. The subsequent full release of data later that same day presented results that appeared clinically positive and exceeded analyst expectations, yet the share price movement suggested investor sentiment had been dampened by the leak itself.
The vaccine, called intismeran autogene, demonstrated notable efficacy when used alongside Merck’s immunotherapy drug Keytruda in treating melanoma. Trial results indicated a 42% reduction in recurrence or death risk compared with Keytruda monotherapy, while also showing a 38% reduction in the risk of cancer spread to distant sites or death. The data revealed that 82% of patients receiving the combination therapy remained free of melanoma recurrence at the two-year mark, compared with 70% of those receiving Keytruda alone. The complete phase 3 trial findings were scheduled to be presented at the European Society for Medical Oncology conference later that week.
Analysts characterized the overall data as positive and clinically meaningful. Multiple research firms attributed the stock decline not to disappointing efficacy but rather to extraordinarily high investor expectations preceding the release. One analyst noted that the reaction appeared to reflect inflated anticipation rather than genuine concerns about the therapy’s effectiveness. Observers also highlighted that upcoming studies examining the vaccine’s potential in kidney and bladder cancers remained a source of confidence in the partnership’s prospects.
Moderna’s shares had experienced substantial gains throughout the year, climbing more than 530% through Thursday afternoon. Merck’s stock, representing a much larger pharmaceutical enterprise, fell approximately 1% on the day, though the company’s shares had gained nearly 41% year-to-date. Industry experts viewed the targeted vaccine as a potentially transformative treatment with applications extending beyond melanoma. For Moderna, the product could provide crucial commercial diversification following its established vaccines for Covid-19, influenza, and respiratory syncytial virus. Manufacturing complexity, requiring approximately six weeks for personalized vaccine production, remains a consideration, though Merck’s chief executive indicated confidence in reducing that timeline over time.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI